|
Patent landscape, scope, and claims: |
United States Patent 7,879,828: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 7,879,828 (U.S. Patent No. 7,879,828) titled “Methods of treating cancer with apatinib” was granted on February 28, 2011. The patent claims a novel method of administering apatinib, a potent VEGFR-2 inhibitor, for treating various cancers. This document offers a thorough review of its scope, claims, and the broader patent landscape surrounding apatinib, highlighting strategic insights for stakeholders in pharmaceutical innovation, licensing, and litigation.
Introduction
The patent under review significantly contributes to the oncology therapeutic space by detailing methods of treating cancers with a specific tyrosine kinase inhibitor, apatinib. Its claims delineate the scope of protection, focusing on particular dosages, administration routes, and cancer types. Understanding this patent's scope is vital for competitive positioning, licensing negotiations, and infringement assessments.
Patent Overview: Basic Details
| Item |
Details |
| Patent Number |
7,879,828 |
| Issue Date |
February 28, 2011 |
| Filing Date |
May 9, 2008 |
| Priority Date |
May 9, 2007 (Chinese Application) |
| Assignee |
Jiangsu Hengrui Medicine Co., Ltd. |
| Inventors |
Zhiyong Zhang, Lianghuan Wang, et al. |
| Title |
“Methods of treating cancer with apatinib” |
Scope of the Patent: Summary
- Field: Oncology, cancer treatment, tyrosine kinase inhibitors.
- Core invention: Use of apatinib for treating various cancers.
- Key Claim Focus: The administration of apatinib, specific dosage regimens, and therapeutic efficacy.
Claims Analysis
Claim Types and Hierarchy
The patent contains independent claims, primarily Claim 1, with accompanying dependent claims that specify dosage, administration frequency, and specific cancer indications.
Claim 1 (Independent Claim) Analysis
"A method for treating cancer in a mammal, comprising administering to the mammal an effective amount of apatinib to inhibit tumor growth."
- Scope: Broad, covering any cancer treated with apatinib.
- Treatment: General, "inhibiting tumor growth," without specifying dosage or administration specifics.
- Implication: Provides a foundational claim that protects the therapeutic use of apatinib across various cancers.
Dependent claims narrow this by specifying:
| Claim Number |
Scope Specification |
Details |
| Claim 2-5 |
Dosage range |
250 mg to 850 mg daily, with specific embodiments at 250, 425, 575, and 850 mg. |
| Claim 6-7 |
Treatment frequency |
Daily administration, with alternative schedules (e.g., twice weekly). |
| Claim 8-10 |
Cancer types |
Gastric, lung, liver, breast, and other solid tumors. |
| Claim 11-15 |
Administration route |
Oral preferred, but covers other routes. |
Claim Scope Specificity
| Claim Number |
Scope Type |
Key Features |
Limitations |
| Claim 1 |
Broad |
Any cancer, any dose, any route |
No specifics, wide protection |
| Claim 2-5 |
Narrow |
Defined dosage ranges |
Limits scope to specific doses |
| Claim 6-7 |
Moderate |
Schedules of administration |
Adds temporal scope |
| Claim 8-10 |
Specific indication |
Certain cancers |
Limits scope geographically and indication-wise |
| Claim 11-15 |
Technical specifics |
Routes and formulations |
Patentability extends to formulations |
Note: The broadness of Claim 1 makes it essential for patent enforcement and litigation to analyze potential infringement meticulously.
Patent Landscape for Apatinib and Similar Tyrosine Kinase Inhibitors
Key Patent Families and Related Rights
| Patent Family |
Filing Countries |
Focus |
Status |
Key Assignee |
| Hengrui Family |
US, CN, EP, JP |
Apatinib composition, methods |
Pending/Granted |
Jiangsu Hengrui Medicine |
| Other Competitor Patents |
US, EU, JP |
Similar VEGFR inhibitors (e.g., Sorafenib, Regorafenib) |
Varying |
Multiple (GSK, Bayer, Regeneron) |
Market Sector and Existing Patents
Apatinib was first approved in China (2014) for advanced gastric cancer. Several patents cover composition of matter, methods of synthesis, and manufacturing.
Comparison Table:
| Patent / Patent Family |
Focus |
Jurisdictions |
Filing & Grant Date |
Status |
| US Patent 7,879,828 |
Treatment methods |
US |
2008 / 2011 |
Granted |
| CN Patent Application CN101839187 |
Composition of matter |
China |
2007 |
Filed / Pending |
| EP Patent EP2453347 |
Medical use of similar inhibitors |
Europe |
2010 |
Pending |
Legal and Patent Policy Context
- First-to-file system in the US emphasizes early filings.
- Patent term: Generally 20 years from filing date.
- Data exclusivity: US law offers additional market exclusivity in certain situations.
- Patent challenges: Articulation of claims' broadness can invite validity challenges, notably on obviousness or lack of novelty.
Critical Analysis of Patent Scope and Limitations
Strengths
- Broad Treatment Coverage: Encompasses multiple cancers, doses, and administration routes.
- Method of Use: Protects use of apatinib specifically for cancer treatment.
- Specific Dosing: Helpful for defining clinical protocols.
Potential Weaknesses
- Lack of Composition of Matter Claims: Absence of patent claims on the chemical structure of apatinib itself. The patent's protection hinges on the method of administration.
- Possible Prior Art Challenges: Use of similar VEGFR inhibitors may challenge novelty or inventive step.
- Limited Claims on Combinatorial Therapies: No claims covering combination treatments, which are common in oncology.
Comparison with Similar Anti-Cancer Agents
| Agent |
Composition of Matter Patent |
Therapeutic Indication |
Approval Status |
Patent Expiry Approx. |
| Apatinib (this patent) |
Not claimed |
Various solid tumors |
Approved in China |
2028 in China |
| Sorafenib (Nexavar) |
US Patent 6,456,221 (expires 2022) |
Liver, renal carcinomas |
Approved globally |
2022 (US) |
| Regorafenib (Stivarga) |
US Patent 8,031,206 (expires 2023) |
Colorectal, liver cancers |
Approved |
2023 |
Note: Composition of matter patents generally provide stronger protection than method patents but are absent here.
Regulatory and Market Implications
- Patent Protection: The granted patent extends market exclusivity for treatment methods in the US until approximately 2031, considering patent term adjustments.
- Off-label Use: Physicians may prescribe off-label, but patent rights restrict commercialization and marketing.
- Generic Entry: Possible after patent expiry; patent landscape influences timing of generic development.
Conclusion: Strategic Considerations
- The patent’s broad method claims offer significant protection but may face validity challenges due to prior art in anti-angiogenic therapies.
- Lack of composition of matter claims limits protection against generic versions made with different chemical processes.
- Companies should consider patent landscaping around related VEGFR inhibitors and combination therapies.
- Licensing efforts should target claims covering specific dosages and indications, with an eye toward clinical development pathways.
Key Takeaways
- U.S. Patent 7,879,828 shields therapeutic methods of using apatinib for cancer treatment, with broad claims covering multiple cancers and administration routes.
- While method claims are valuable, the absence of composition of matter claims may restrict enforcement against generic equivalents.
- The patent landscape indicates a competitive environment with existing and emerging patents on similar VEGFR inhibitors, necessitating strategic patent positioning.
- Stakeholders should monitor ongoing patent prosecutions, potential challenges, and evolving regulatory data to inform commercialization strategies.
- The patent’s expiry around 2031 provides a window for exclusive marketing until then, after which generic competition may enter.
FAQs
1. Does U.S. Patent 7,879,828 cover the chemical structure of apatinib?
No, it primarily covers treatment methods involving apatinib, not the composition of matter. Composition claims, which provide more direct chemical protection, are absent.
2. Can a competitor produce the same treatment using a different VEGFR-2 inhibitor without infringing?
Yes, if they use a different compound with a substantially different chemical structure or mechanism, they may avoid infringement. Only the methods involving apatinib specifically are protected.
3. What are the major limitations of this patent?
Limitations include the focus on method claims without composition of matter protection and potential challenges based on prior art given the broad treatment claims.
4. How does this patent compare to those on similar agents like sorafenib or regorafenib?
Unlike sorafenib or regorafenib, which possess composition of matter patents, this patent centers on treatment methods, making direct competition more nuanced and requiring detailed legal and technical assessments.
5. When does patent expiry occur, and what are the implications for market exclusivity?
Typically, the patent expires around 2031, providing exclusive rights until then. Post-expiry, generics can enter the market, reducing costs and increasing competition.
References
- U.S. Patent and Trademark Office. "United States Patent 7,879,828." Issued Feb. 28, 2011.
- Jiangsu Hengrui Medicine Co., Ltd. Public disclosures and filings.
- World Health Organization. "Apatinib approval facts," 2014.
- European Patent Office. "Patent Landscape Reports on VEGFR Inhibitors," 2020.
- Food and Drug Administration. “Apatinib NDA Summary,” 2014.
For comprehensive patent guidance and legal advice, stakeholders should perform thorough patent searches and patentability analyses tailored to their specific development pipeline.
More… ↓
⤷ Get Started Free
|
